Literature DB >> 15324352

Initial antimicrobial effect of controlled-release doxycycline in subgingival sites.

M G Jorgensen1, A Safarian, N Daneshmand, R J Keim, J Slots.   

Abstract

OBJECTIVES: To determine the ability of a 10% doxycycline hyclate controlled-release polymer (Atridox) to suppress periodontopathic bacteria when placed subgingivally following scaling and root planing (Sc/Rp).
METHODS: Eight males and seven females, mean age 48 years, with moderate to advanced periodontitis participated in the study. In each patient, bilateral periodontal pockets probing 6-7 mm were randomly assigned to treatment by Sc/Rp + doxycycline polymer or by Sc/Rp alone. Subgingival placement of doxycycline polymer was carried out according to the manufacturer's instructions. Sc/Rp was performed with hand instruments for at least 10 min in each study tooth. Subgingival samples were collected by paper-points at baseline, at 2 weeks and at 4 weeks post-treatment. Culture methodology was used to isolate and identify putative periodontal pathogens, including Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Dialister pneumosintes, Tannerella forsythia, Prevotella intermedia/Prevotella nigrescens, Campylobacter species, Eubacterium species, Fusobacterium species, Peptostreptococcus micros, Eikenella corrodens, Staphylococcus species, enteric gram-negative rods, beta-hemolytic streptococci and yeasts. The microbiologic examination was carried out blindly. Microbiological data were analyzed using a General Linear Model Analysis of Variance for within and between group effects.
RESULTS: Sites receiving Sc/Rp + doxycycline polymer and sites receiving Sc/Rp alone exhibited similar levels of periodontal pathogens at baseline and did not differ significantly in total viable counts and proportional recovery of periodontopathic bacteria post-treatment.
CONCLUSIONS: Controlled-release doxycycline placed in moderate to deep periodontal pockets caused no significant additional reduction in the subgingival pathogenic microbiota compared to thorough Sc/Rp alone. Since controlled-release doxycycline may not significantly suppress several subgingival pathogenic microorganisms and seems to possess no distinct advantage over broad-spectra, safe and inexpensive antiseptics, the rationale for its employment in periodontal therapy remains unclear.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15324352     DOI: 10.1111/j.1600-0765.2004.00742.x

Source DB:  PubMed          Journal:  J Periodontal Res        ISSN: 0022-3484            Impact factor:   4.419


  5 in total

1.  The effect of locally delivered doxycycline as an adjunctive therapy to scaling and root planing in smokers.

Authors:  Hassan Al Hulami; Nadir Babay; Fatin Awartani; Sukumaran Anil
Journal:  Saudi Dent J       Date:  2011-05-03

2.  Clinical and microbiological results following nonsurgical periodontal therapy with or without local administration of piperacillin/tazobactam.

Authors:  Marc Lauenstein; Marion Kaufmann; G Rutger Persson
Journal:  Clin Oral Investig       Date:  2013-01-20       Impact factor: 3.573

3.  Evaluating the effect of probiotic supplementation in the form of mouthwash along with scaling and root planing on periodontal indices in patients with stage III and grade A generalized periodontitis: A randomized clinical trial.

Authors:  Shima Ghasemi; Amir Reza Babaloo; Behnam Mohammadi; Mahdieh Esmailzadeh
Journal:  J Adv Periodontol Implant Dent       Date:  2020-12-09

4.  Green tea extract as a local drug therapy on periodontitis patients with diabetes mellitus: A randomized case-control study.

Authors:  Jayaprakash S Gadagi; Vijay K Chava; Venkata Ramesh Reddy
Journal:  J Indian Soc Periodontol       Date:  2013-03

5.  The effect of locally delivered doxycycline in the treatment of chronic periodontitis. A clinical and microbiological cohort study.

Authors:  Ioannis Ioannou; Nikolaos Dimitriadis; Konstantinos Papadimitriou; Ioannis Vouros; Dimitra Sakellari; Antonis Konstantinidis
Journal:  J Oral Maxillofac Res       Date:  2011-01-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.